Sophiris Eyes Another Phase III After Positive BPH Results
This article was originally published in Scrip
Sophiris Bio Inc. bounced back from a negative interim efficacy report when the company revealed positive results from the Phase III PLUS-1 clinical trial for PRX302 (topsalysin) in the treatment of urinary tract symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, on Nov. 10.
You may also be interested in...
The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.